A Phase 3 interventional study of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) and Placebo in Carcinoma and Non Small Cell Lung, sponsored by Sanofi. Completed at 32 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 402 studies in Carcinoma with a site in United States — 70 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.
Among the 402 studies in Carcinoma with a site in United States, this one is the 9th largest by enrollment of the 358 interventional ones that give a count, is one of 10 that started in 2007, is one of 49 in phase 3, and was the 67th registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →70 of the 402 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120 · Men only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Pfizer · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
402 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 161 · Phase 2 171 · Phase 3 53 · Phase 4 7
First in 1996; this study’s year is marked. 10 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 913 is above the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 48 across the 358 interventional studies, 108 across the 40 observational. Of the 267 that completed or were terminated, 121 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 402 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 9 studies filed under Carcinoma — fewer than ten, so there is no comparison to draw.
35 of the studies in Carcinoma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05050162Phase 3NRG OncologyComparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer | 2027-02-09 |
| NCT06693336ToLymph Inc.An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer | 2026-11-18 |
| NCT04520711Providence Health & ServicesHotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | 2026-12 |
| NCT05768932SillaJen, Inc.BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | 2026-12-24 |
Add all 35 to your calendar (.ics) → With an account.
Among the 402 studies in Carcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC).
The secondary objectives were to compare other efficacy parameters, to assess the overall safety of the two treatment arms, to assess the pharmacokinetics of intravenous (IV) aflibercept in this participant population and to determine immunogenicity of IV aflibercept in all participants.
The study included:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information was not intended to contain all considerations relevant to participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) · Drug: Docetaxel (Taxotere®) · Drug: Dexamethasone (pre- and post-medication for docetaxel)
Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
Drug: Placebo · Drug: Docetaxel (Taxotere®) · Drug: Dexamethasone (pre- and post-medication for docetaxel)
6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
Drug page: Dexamethasone
As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
Overall Survival (OS)
OS was time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, overall survival time was censored at the last date the participant was known to be alive, or the study cutoff date, whichever was earlier. The cut-off date for the OS was date when 687 deaths were observed. OS was estimated from Kaplan-Meier Curves.
Time frame: Baseline to the date when 687 deaths occurred (26 January 2011)
Progression Free Survival (PFS)
PFS was defined as the time interval between the date of randomization and the time of occurrence of the first radiological tumor progression detected by a computer tomography (CT) scan and /or by Magnetic Resonance Imaging (MRI); or death due to any cause; whichever was earlier. Participants without disease progression were censored at the earliest date between their last valid tumour assessment and the data cutoff date. PFS was estimated from Kaplan-Meier Curves.
Time frame: Baseline to data cut-off (26 January 2011)
Overall Response (OR) Rate as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria
Participants with OR were those who had a confirmed complete response \[CR\] or a confirmed partial response \[PR\], based on RECIST criteria, in which * CR refected the disappearance of all tumor lesions (with no new tumors) * PR reflected a pre-defined decrease in tumor burden - a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD * OR was CR + PR The response rate was the percent of participants with a response. To determine a response, tumors were assessed by the investigators using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.
Time frame: Baseline to data cut-off (26 January 2011)
Health Related Quality of Life (HRQL) Assessed by the Lung Cancer Symptom Scale (LCSS)
HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies (appetite, fatigue, cough, dyspnea, hemoptysis and pain), and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. The LCSS total score was defined as the mean of the 9 items of the scale, each scored between 0 (for best outcome) to 100 (for worst outcome).
Time frame: Baseline (prior to first dose), at cycles 2 and 4 and at the end of study therapy.
Health Related Quality of Life (HRQL) Assessed by the Average Symptom Burden Index (ASBI)
HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies, and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. ABSI was the mean score for the six major lung cancer symptoms (appetite, fatigue, cough, dyspnea, hemoptysis and pain), each scored between 0 (for best outcome) to 100 (for worst outcome).
Time frame: Baseline (prior to first dose), at cycles 2 and 4 and at the end of study therapy.
| Milestone | Placebo/Docetaxel | Aflibercept/Docetaxel |
|---|---|---|
| Started | 457 | 456 |
| Safety population | 455 | 450 |
| Completed | 0 | 0 |
| Not completed | 457 | 456 |
| Withdrew: Adverse event | 66 | 123 |
| Withdrew: Lack of efficacy | 332 | 255 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Physician decision | 16 | 15 |
| Withdrew: Withdrawal by subject | 23 | 44 |
| Withdrew: Consent withdrawn | 5 | 7 |
| Withdrew: Moved | 1 | 0 |
| Withdrew: Pre-existing brain metastasis (by mri) | 1 | 0 |
| Withdrew: Occurence of a second cancer | 0 | 1 |
| Withdrew: Occurence of a secondary cancer | 0 | 1 |
| Withdrew: Promotor ended study | 1 | 0 |
| Withdrew: Progressive disease (by incorrect scan) | 0 | 1 |
| Withdrew: Had brain metastasis, was mis-randomized | 1 | 0 |
| Withdrew: Study stopped | 1 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 0 |
| Withdrew: Study termination stop further treatment | 4 | 0 |
| Withdrew: Did not receive study medication | 2 | 6 |
OS was time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, overall survival time was censored at the last date the participant was known to be alive, or the study cutoff date, whichever was earlier. The cut-off date for the OS was date when 687 deaths were observed. OS was estimated from Kaplan-Meier Curves.
| months | Placebo/Docetaxel | Aflibercept/Docetaxel |
|---|---|---|
| Overall Survival (OS) | 10.41 (9.199 to 11.860) | 10.05 (9.166 to 11.598) |
PFS was defined as the time interval between the date of randomization and the time of occurrence of the first radiological tumor progression detected by a computer tomography (CT) scan and /or by Magnetic Resonance Imaging (MRI); or death due to any cause; whichever was earlier. Participants without disease progression were censored at the earliest date between their last valid tumour assessment and the data cutoff date. PFS was estimated from Kaplan-Meier Curves.
| months | Placebo/Docetaxel | Aflibercept/Docetaxel |
|---|---|---|
| Progression Free Survival (PFS) | 4.11 (3.515 to 4.337) | 5.19 (4.370 to 5.552) |
Participants with OR were those who had a confirmed complete response \[CR\] or a confirmed partial response \[PR\], based on RECIST criteria, in which * CR refected the disappearance of all tumor lesions (with no new tumors) * PR reflected a pre-defined decrease in tumor burden - a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD * OR was CR + PR The response rate was the percent of participants with a response. To determine a response, tumors were assessed by the investigators using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.
| percentage of participants | Placebo/Docetaxel | Aflibercept/Docetaxel |
|---|---|---|
| Complete Response (CR) rate | 0.2 | 0.2 |
| Partial Response (PR) rate | 8.6 | 23.0 |
| Overall Response (OR) rate | 8.9 | 38.6 |
HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies (appetite, fatigue, cough, dyspnea, hemoptysis and pain), and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. The LCSS total score was defined as the mean of the 9 items of the scale, each scored between 0 (for best outcome) to 100 (for worst outcome).
| units on a scale | Placebo/Docetaxel | Aflibercept/Docetaxel |
|---|---|---|
| Baseline (N=431, N=428) | 29.52 ± 17.03 | 31.54 ± 18.03 |
| Cycle 2 (N=329, N=315) | 29.50 ± 16.72 | 30.54 ± 16.78 |
| Cycle 4 (N=211, N=240) | 27.67 ± 16.24 | 29.61 ± 16.92 |
| End of treatment (N=254, N=240) | 34.82 ± 18.34 | 36.07 ± 18.81 |
HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies, and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. ABSI was the mean score for the six major lung cancer symptoms (appetite, fatigue, cough, dyspnea, hemoptysis and pain), each scored between 0 (for best outcome) to 100 (for worst outcome).
| units on a scale | Placebo/Docetaxel | Aflibercept/Docetaxel |
|---|---|---|
| Baseline (N=429, N=429) | 26.17 ± 16.30 | 28.24 ± 16.91 |
| Cycle 2 (N=327, N=316) | 26.23 ± 15.93 | 27.05 ± 15.92 |
| Cycle 4 (N=211, N=241) | 24.52 ± 15.22 | 26.19 ± 16.38 |
| End of treatment (N=253, N=239) | 30.73 ± 17.26 | 31.19 ± 18.12 |
Collected over From treatment initiation to October 21, 2011. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Docetaxel | — | 159/453 (35.1%) | 388/453 (85.7%) |
| Aflibercept/Docetaxel | — | 218/452 (48.2%) | 402/452 (88.9%) |
| Event | Placebo/Docetaxel | Aflibercept/Docetaxel |
|---|---|---|
| Disease progressionGeneral disorders | 12/453 | 33/452 |
| Febrile neutropeniaBlood and lymphatic system disorders | 17/453 | 21/452 |
| PneumoniaInfections and infestations | 20/453 | 15/452 |
| NeutropeniaBlood and lymphatic system disorders | 7/453 | 16/452 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 14/453 | 13/452 |
| StomatitisGastrointestinal disorders | 0/453 | 13/452 |
| Neutropenic infectionInfections and infestations | 11/453 | 11/452 |
| Neutropenic sepsisInfections and infestations | 3/453 | 10/452 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 8/453 | 8/452 |
| DiarrhoeaGastrointestinal disorders | 3/453 | 8/452 |
| Event | Placebo/Docetaxel | Aflibercept/Docetaxel |
|---|---|---|
| StomatitisGastrointestinal disorders | 69/453 | 180/452 |
| AlopeciaSkin and subcutaneous tissue disorders | 148/453 | 133/452 |
| FatigueGeneral disorders | 130/453 | 142/452 |
| DiarrhoeaGastrointestinal disorders | 106/453 | 124/452 |
| Decreased appetiteMetabolism and nutrition disorders | 93/453 | 122/452 |
| Weight decreasedInvestigations | 35/453 | 110/452 |
| CoughRespiratory, thoracic and mediastinal disorders | 94/453 | 108/452 |
| HypertensionVascular disorders | 23/453 | 95/452 |
| NauseaGastrointestinal disorders | 92/453 | 79/452 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 28/453 | 90/452 |
| Age, Continuous(Years) | Placebo/Docetaxel | Aflibercept/Docetaxel | Total |
|---|---|---|---|
| Mean | 59.6 ± 9.4 | 59.6 ± 9.5 | 59.6 ± 9.4 |
| Age, Customized(participants) | Placebo/Docetaxel | Aflibercept/Docetaxel | Total |
|---|---|---|---|
| <65 years | 316 | 315 | 631 |
| >= and <75 years | 122 | 121 | 243 |
| >=75 years | 19 | 20 | 39 |
| Sex/Gender, Customized(participants) | Placebo/Docetaxel | Aflibercept/Docetaxel | Total |
|---|---|---|---|
| Male | 300 | 305 | 605 |
| Female | 157 | 151 | 308 |
| Race/Ethnicity, Customized(participants) | Placebo/Docetaxel | Aflibercept/Docetaxel | Total |
|---|---|---|---|
| Caucasian/White | 405 | 411 | 816 |
| Black | 10 | 7 | 17 |
| Asian/Oriental | 40 | 34 | 74 |
| Other | 2 | 4 | 6 |
| Body Surface Area (BSA)(m²) | Placebo/Docetaxel | Aflibercept/Docetaxel | Total |
|---|---|---|---|
| Mean | 1.8 ± 0.2 | 1.8 ± 0.2 | 1.8 ± 0.2 |
| Prior Bevacizumab (as per IVRS)(participants) | Placebo/Docetaxel | Aflibercept/Docetaxel | Total |
|---|---|---|---|
| Yes | 53 | 51 | 104 |
| No | 404 | 405 | 809 |
| Eastern Cooperative Oncology Group (ECOG) performance status score (as per IVRS)(participants) | Placebo/Docetaxel | Aflibercept/Docetaxel | Total |
|---|---|---|---|
| Participants with ECOG Score = 0 | 151 | 149 | 300 |
| Participants with ECOG Score = 1 | 283 | 286 | 569 |
| Participants with ECOG Score = 2 | 23 | 21 | 44 |
The record gives a start of Sep 2007, a primary completion of Jan 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 2 years after primary completion. A results delay was requested in Feb 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept